Glucotrack Stock Price, News & Analysis

Glucotrack (Nasdaq: GCTK) named Usman Latif, MD, MBA to its clinical advisory team on October 29, 2025 to guide development of integrated glucose monitoring for painful diabetic neuropathy (PDN) and epidural monitoring.

Dr. Latif is an anesthesiologist and neuromodulation expert with academic appointments and clinical fellowships at institutions including Johns Hopkins, Harvard/Mass General, Yale, and University of Kansas. The company said it completed a long-term preclinical study showing feasibility and safety of epidural glucose monitoring and continues development of its implantable CBGM system with 3-year sensor longevity.

PDN affects roughly one-fifth of >38 million Americans with diabetes (~7 million people). The CBGM is an investigational device and Glucotrack highlighted regulatory, clinical trial, and financing risks.

Glucotrack (Nasdaq: GCTK) will hold a Special Meeting of Shareholders on October 31, 2025 at 12:00 p.m. ET for a shareholder vote on an Equity Purchase Agreement with Sixth Borough Capital. Shareholders of record as of September 23, 2025 are eligible to vote. The Board of Directors unanimously recommends voting "FOR" all proposals.

Shareholders are urged to vote early by telephone, online, or by returning a signed proxy card. The Company filed its definitive proxy statement with the SEC on October 3, 2025, and additional information is available at www.sec.gov. Voting assistance is available from proxy solicitors Sodali & Co. at 1-888-777-2094 or GCTK.info@investor.sodali.com.

Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes technologies, has announced its participation in the upcoming Q3 Virtual Investor Summit. Paul V. Goode, PhD, the company's President and CEO, will lead the presentation on Tuesday, September 16, 2025, at 1:30 PM ET.

The event will include a company presentation and one-on-one meetings with investors, providing an opportunity for stakeholders to learn more about Glucotrack's developments in diabetes technology.

Glucotrack (NASDAQ:GCTK), a medical technology company developing novel diabetes technologies, reported significant progress in Q2 2025. The company is preparing to launch a multicenter feasibility study of its fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025, followed by an FDA IDE submission in Q4 2025.

Key developments include strengthening the leadership team with Dr. David Hirsh as Medical Director-Cardiology and Dr. Victoria Carr-Brendel joining the Board. Clinical data presented at the ADA conference showed excellent accuracy with a MARD of 7.7% and 99% data capture rate. The company reported $9.6 million in cash as of June 30, 2025, sufficient to fund operations through 2025.

Financial results showed R&D expenses of $5.0 million and net loss of $11.6 million for H1 2025. The company strengthened its capital structure by repurchasing Series A Warrants to eliminate warrant liability and dilution concerns.

Glucotrack (NASDAQ:GCTK) has appointed Dr. David S. Hirsh as Medical Director of Cardiology to support the development of their Continuous Blood Glucose Monitor (CBGM). Dr. Hirsh, an experienced cardiac electrophysiologist from Harbin Clinical Cardiology Rome, brings extensive expertise in interventional cardiology procedures.

The appointment strengthens Glucotrack's clinical leadership as they advance their long-term implantable CBGM system, which is designed for up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, aiming to provide real-time readings without lag time. The system features a unique intravascular placement approach and requires no wearable component.

Glucotrack (NASDAQ:GCTK) announced its participation in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting from August 8-11, 2025 in Phoenix, AZ. The company will showcase its innovative Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a scientific poster on endocrinologist perspectives regarding implantable monitoring technology.

Glucotrack's CBGM technology represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. The company is preparing to begin its long-term early feasibility study following successful initial clinical validation.

Glucotrack (Nasdaq: GCTK) has announced the successful repurchase of over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The company repurchased approximately 49,700 Series A Warrants using existing cash, with about 4,300 warrants remaining outstanding. The warrants were originally issued as part of a $10M Public Offering in November 2024.

The repurchase is part of Glucotrack's capital formation strategy and demonstrates confidence in its development of a long-term implantable continuous blood glucose monitoring system for diabetes patients. The company's Series B Warrants were previously converted to common stock, as reported in Q1 2025.

Glucotrack (NASDAQ:GCTK) has announced positive final results from its first-in-human clinical study for its innovative Continuous Blood Glucose Monitor (CBGM) at the American Diabetes Association's 85th Scientific Sessions. The study demonstrated excellent accuracy with a MARD of 7.7% across 122 matched pairs and a 99% data capture rate, with no serious adverse events.

The implantable CBGM technology measures glucose directly from blood rather than interstitial fluid, eliminating typical lag time associated with traditional monitors. The study, conducted in Brazil from December 2024 to January 2025, included ten Type 1 or Type 2 diabetes patients. Analysis showed 92% of measurements in the green zone of the Diabetes Technology Society Error Grid, indicating high clinical accuracy.

The company plans to initiate a long-term early feasibility study in Q3 2025. The CBGM system is designed for a three-year sensor life with no on-body wearable component and minimal calibration requirements.

Glucotrack (NASDAQ: GCTK) announced a 1-for-60 reverse stock split effective June 16, 2025, aimed at maintaining its NASDAQ listing compliance. The company's outstanding common stock will be reduced from 32,541,327 to approximately 542,356 shares, with stockholders' ownership percentages remaining unchanged except for fractional shares being rounded up. The split was approved by shareholders on May 22, 2025, authorizing management to implement a ratio up to 1-for-100. This strategic move is primarily intended to meet NASDAQ's $1.00 minimum bid price requirement and attract institutional life science investors. The company must maintain compliance with NASDAQ listing rules through September 29, 2025, to avoid potential delisting.